Van ECK Associates Corp Has $43.77 Million Position in Novo Nordisk A/S $NVO

Van ECK Associates Corp increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 18.0% in the third quarter, Holdings Channel reports. The institutional investor owned 788,722 shares of the company’s stock after buying an additional 120,127 shares during the period. Van ECK Associates Corp’s holdings in Novo Nordisk A/S were worth $43,766,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Martin Capital Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after buying an additional 41,129 shares during the last quarter. Smith Chas P & Associates PA Cpas increased its holdings in Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after buying an additional 207,959 shares during the last quarter. Clifford Swan Investment Counsel LLC raised its position in Novo Nordisk A/S by 13.7% during the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock worth $17,267,000 after acquiring an additional 37,453 shares in the last quarter. Markel Group Inc. lifted its stake in Novo Nordisk A/S by 4.9% in the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after acquiring an additional 110,061 shares during the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. bought a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $1,294,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.2%

Shares of NVO opened at $38.82 on Thursday. The firm has a market cap of $173.31 billion, a P/E ratio of 11.19 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $82.57. The firm’s 50-day simple moving average is $50.69 and its 200 day simple moving average is $52.02.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 52.74%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. The Goldman Sachs Group reiterated a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective on the stock. in a research note on Tuesday. Nordea Equity Research downgraded Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Finally, CICC Research began coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $49.93.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Zacks Research upgraded Novo from “strong sell” to “hold,” which can temper selling pressure and signal some stabilization to investors. Zacks.com
• Positive Sentiment: New commercial channel: Novo ended its feud with Hims & Hers and agreed to sell Ozempic and Wegovy on the Hims platform — that broadens distribution and could recapture patients moving to compounded GLP?1s. Novo and Hims & Hers become partners to end legal feud
• Positive Sentiment: WHO Foundation partnership: Novo committed roughly $8M to WHO Foundation initiatives on cardiorenal?metabolic diseases, extending global health reach and supporting longer?term reputation/market access in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Novo Holdings 2025 results: stable income and returns at the foundation level (DKK 21bn) provide context on group cash flows but are a second?order signal for NVO’s near?term share moves. Novo Holdings announces 2025 Annual Results
• Negative Sentiment: FDA warning letter over post?marketing adverse event reporting for semaglutide (Ozempic/Wegovy) is the largest near?term risk: regulators cited failures to follow reporting procedures, and coverage highlights linked deaths — this raises compliance risk and valuation uncertainty. FDA Warning Letter Puts Novo Nordisk Compliance And Valuation In Focus
• Negative Sentiment: Analyst pressure: TD Cowen and other brokers trimmed ratings/targets and coverage changes have driven intraday selling and downward revisions to near?term expectations. Novo Nordisk A/S (NYSE:NVO) Stock Rating Lowered by TD Cowen
• Negative Sentiment: Legal/investor risk: a Pomerantz investigation and reports of trading down after analyst downgrades amplify litigation and sentiment risks that can pressure the share price. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO
• Negative Sentiment: Competitive and pipeline concerns: reports that rivals (notably Eli Lilly and other entrants) are expanding aggressively and that Novo’s pipeline may not blunt semaglutide LOE are longer?term threats to growth and valuation. Novo Nordisk: Buying The Dip Before Volume Dominance

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.